Surgery Partners, Inc. (SGRY) Stock Analysis

Company Overview

Surgery Partners, Inc. owns and operates an extensive network of surgical facilities and ancillary services throughout the United States, providing ambulatory surgery centers and surgical hospitals that perform non-emergency procedures across various medical specialties. This organization functions within the Healthcare sector, specifically the Medical Care Facilities industry, positioning it as a key provider of elective surgical care rather than emergency services. The company demonstrates significant scale with a market capitalization of $1.54B, annual revenue of $3.31B, and an employee base of 16000 individuals supporting its operational network. These valuation and revenue figures indicate that the entity represents a substantial mid-to-large-cap player in the healthcare infrastructure space, though the negative net income suggests the current scale is not yet translating into profitability. The disparity between the $3.31B in revenue and the $1.54B market cap further highlights the market's pricing of the business based on future earnings potential rather than current asset value or immediate profit generation.

Financial Health

The company reports revenue of $3.31B over the trailing twelve months, yet it posts a net income of $-77,900,000, revealing a cost structure where operating expenses significantly outweigh the gross profits generated from surgical services. Despite the net loss, the entity maintains an EBITDA of $655.50M, indicating that the core operational cash generation remains robust even when accounting for non-operating expenses and taxes. The free cash flow stands at $164.71M, which signifies that the company possesses sufficient liquidity from operations to fund capital expenditures or service debt without relying on external financing. Margin analysis shows a gross margin of 23.1%, an operating margin of 15.1%, and a profit margin of -2.4%, illustrating that while the pricing power covers direct costs and some overhead, the bottom line is currently eroded by high fixed costs or interest expenses. On the balance sheet, cash holdings of $239.90M are substantially lower than the total debt of $4.04B, and the debt-to-equity ratio of 114.51 confirms that the company is highly leveraged with liabilities exceeding equity. The current ratio of 1.87 suggests that the company maintains a conservative short-term liquidity position with current assets exceeding current liabilities by a comfortable margin. Return on Equity of 2.8% and Return on Assets of 3.7% indicate that management effectiveness is currently limited by the high debt load and lack of net income, as returns are calculated on a negative equity base or inflated asset values.

Valuation Assessment

The trailing P/E ratio is listed as N/A due to the negative net income, whereas the forward P/E is 27.02, implying that the market is pricing in a significant expected recovery in earnings to reach a positive multiple in the near future. The price-to-book ratio of 0.89 indicates that the stock is trading below its book value, suggesting the market currently discounts the asset base or expects future earnings to remain suppressed until structural changes occur. Alternative valuation metrics include a price-to-sales ratio of 0.47 and an EV/EBITDA of 10.87, which suggest the company is valued at a discount relative to its sales and operational cash flow compared to typical profitable peers in the medical sector. The 52-week high is $24.60 and the 52-week low is $11.61, and without a specific current price provided in the data, the valuation range indicates a wide trading band of approximately 129% volatility between the recent peaks and troughs. The beta of 1.94 reveals that the stock price exhibits high volatility relative to the broader market, moving with nearly double the intensity of the overall index during periods of market fluctuation.

Growth & Income

Revenue growth for the trailing twelve months is 2.4%, while earnings growth is N/A due to the reported net loss, indicating that top-line expansion is currently occurring without corresponding bottom-line improvement. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means all available cash flow is retained to service debt or fund operations rather than being distributed to shareholders. Since the payout ratio is zero, the company is effectively reinvesting its free cash flow into the business to potentially reduce the $4.04B debt load or invest in facility expansion to improve margins. The overall growth and income profile reflects a capital-intensive turnaround phase where revenue stability is being prioritized over income generation and shareholder distributions.